北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2025 年第三次临时股东大会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2025 年第三次临时股东大会的法律意见 北京德恒律师事务所 关于中红普林医疗用品股份有限公司 法律意见 德恒 01G20250295-03 号 致：中红普林医疗用品股份有限公司 中红普林医疗用品股份有限公司（以下简称"公司"）2025 年第三次临时 股东大会（以下简称"本次会议"）于 2025 年 9 月 15 日（星期一）召开。北京 德恒律师事务所（以下简称"德恒"）受公司委托，指派吴莲花律师、荣秋立律 师（以下简称"德恒律师"），根据《中华人民共和国证券法》（以下简称"《证 券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、中国证 券监督管理委员会《上市公司股东会规则》（以下简称"《股东会规则》"）、 《中红普林医疗用品股份有限公司章程》（以下简称"《公司章程》"）的规定， 就本次会议的召集、召开程序、 ...

特此公告 中红普林医疗用品股份有限公司 证券代码：300981 证券简称：中红医疗 公告编号：2025-086 中红普林医疗用品股份有限公司 关于公司补选薪酬考核与提名委员会委员的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 9 月 15 日，中红普林医疗用品股份有限公司（以下简称"公司"） 召开了第四届董事会第十二次会议，审议通过了《关于补选薪酬考核与提名委员 会委员的议案》，同意补选非独立董事詹志东先生（简历见附件）为公司第四届 董事会薪酬考核与提名委员会委员，与张旭东先生（主任委员）、杜汋先生共同 组成第四届董事会薪酬考核与提名委员会，上述任期自本次董事会审议通过之日 起至第四届董事会任期结束之日止。 詹志东先生，男，1974 年出生，中国国籍，无境外永久居住权，高级管理 人员工商管理硕士，高级经济师。曾任厦门国贸资产运营集团有限公司总经理， 厦门国贸会展集团有限公司董事长、总经理，厦门国贸控股集团有限公司董事、 战略投资总监、战略运营管理部总经理、总经理助理等职。现任厦门国贸控股集 团有限公司副总经理，中红普林集团有限公司董事长， ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-084 中红普林医疗用品股份有限公司 关于公司选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 董事会 二〇二五年九月十五日 附件： 根据《公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等法律法规、规范性文件及《公司章程》的有关规定，中 红普林医疗用品股份有限公司（以下简称"公司"）于 2025 年 9 月 15 日召开第 四届职工代表大会第四次会议，选举贾斌先生担任公司第四届董事会职工代表董 事（简历见附件），任期自本次职工代表大会审议通过之日起至第四届董事会届 满之日止。贾斌先生符合相关法律法规、规范性文件及《公司章程》有关董事任 职的资格和条件。贾斌先生当选职工代表董事后，公司第四届董事会中兼任公司 高级管理人员以及由职工代表担任的董事人数总计未超过公司董事总数的二分 之一，符合相关法律法规的要求。 特此公告 中红普林医疗用品股份有限公司 贾斌先生简历 贾斌先生，男，1985 年出生，中国国籍，无境外永久居留权，硕士研究生 学历，高 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-085 中红普林医疗用品股份有限公司 第四届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 中红普林医疗用品股份有限公司（以下简称"公司"）第四届董事会第十二 次会议于 2025 年 9 月 15 日以通讯方式召开，2025 年 9 月 15 日公司以电话和电 子邮件方式向全体董事发出会议通知(全体董事已同意豁免本次临时董事会通知 的时间要求)。会议应参加表决的董事 9 人，实际参加表决董事 9 人，会议由董 事长桑树军先生主持，公司高管和相关人员列席了会议。会议的召集、召开符合 相关法律、法规和公司章程的规定。 二、会议审议情况 1. 审议通过《关于补选薪酬考核与提名委员会委员的议案》 鉴于池毓云先生申请辞去公司董事及薪酬考核与提名委员会委员职务，根据 《公司法》《公司章程》的有关规定，董事会同意选举詹志东先生为第四届董事 会薪酬考核与提名委员会委员，与张旭东先生（主任委员）、杜汋先生共同组成 第四届董事会薪酬考核与提名委员会，上述任期自本次董事会审 ...

Group 1: Company Overview - Zhonghong Pulin Medical Supplies Co., Ltd. is listed under stock code 300981 and is involved in the medical supplies sector [1]. - The company held an investor performance briefing on September 15, 2025, via an online platform [2]. Group 2: Key Business Developments - The company has a stake in Weimai Technology, which focuses on digital vital sign management solutions and emphasizes significant R&D investment, constituting a large portion of its revenue [2][3]. - Weimai Technology's health management software, Xiaomai Shukang, utilizes AI models for predicting symptoms and temperature trends, enhancing patient care during surgeries [3]. Group 3: Financial and Operational Updates - The overall revenue from Weimai Technology's product line is experiencing rapid growth [3]. - The company's general manager is in the process of increasing his shareholding by 50,000 shares, with the completion of this process pending [3].

Core Viewpoint - The article discusses the evolving landscape of the medical device industry in China, highlighting the importance of business development (BD) strategies that go beyond mere numbers to encompass strategic partnerships, market expansion, and technological integration [1][24]. Group 1: Key Trends in Medical Device BD - The primary keywords for the period from July to September include cross-border introduction and global distribution, strategic cooperation, and capital and cross-industry integration [2]. - Companies are accelerating market expansion and ecosystem building through transactions across various fields, including cardiovascular, neuro-intervention, ophthalmology, IVD, and critical care [3]. Group 2: Representative Events - A total of 20 significant events were summarized, showcasing a "multi-line advancement" scenario in the industry [4]. - Notable collaborations include: - Nanjing Jianxin Medical and Heqi Family Office focusing on medical device R&D and wealth management [6]. - Olympus and Xingchenhai Medical signing a global distribution agreement for disposable urology products [6]. - He’s Eye Group and Zeiss China Medical forming a strategic partnership to enhance ophthalmic surgical technology [6]. Group 3: Cross-Border and Global Distribution - Cross-border transactions remain a hot topic, with domestic companies leveraging global markets for growth while foreign giants introduce Chinese innovations [9]. - The partnership between Ruichao Dinkai Group and Beijing Amite focuses on vascular intervention products, marking a new phase in safety standards [7]. Group 4: Strategic Cooperation and Channel Expansion - Strategic cooperation is increasingly focused on building ecosystems rather than single product breakthroughs, with companies forming partnerships in fields like ophthalmology, IVD, and diagnostics [19]. - The collaboration between Wanfu Biological and Beiden Medical aims to match products with non-public medical channels effectively [15]. Group 5: Capital Support and Cross-Industry Integration - Capital is becoming an invisible driver of medical device BD, with partnerships exploring new models for medical device distribution [20]. - The collaboration between Beijing Huamai Supply Chain Management and Hongyi Consulting aims to create a one-stop service for medical device distribution [20]. Group 6: Smart Hospitals and Full-Chain Coordination - The focus on smart hospitals and full-chain coordination is becoming a priority for large enterprises, integrating supply chains, academic promotion, and clinical needs [23]. - Collaborations like that of Ruibo Zehou Technology and China National Pharmaceutical Group aim to develop automated systems for smart hospitals [21]. Conclusion - The medical device industry in China is transitioning from a "single product-driven" phase to a more diversified approach supported by capital, channels, and ecosystems, indicating a long-term growth trajectory [24].

关于参加 2025 年河北辖区上市公司投资者网上集体接待日 证券代码：300981 证券简称：中红医疗 公告编号：2025-082 暨 2025 年半年报集体业绩说明会的公告 中红普林医疗用品股份有限公司 中红普林医疗用品股份有限公司 董事会 二〇二五年九月十日 为进一步加强与投资者的互动交流，中红普林医疗用品股份有限公司（以下 简称"公司"）将参加由河北省上市公司协会与河北资本市场之家主办的"2025 年河北辖区上市公司投资者网上集体接待日暨 2025 年半年报集体业绩说明会"， 现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 (http://rs.p5w.net)，或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 9 月 15 日（周一）15:00-17:00。 届时公司总经理杨浩女士、副总经理兼财务总监王文龙先生、董事会秘书张 琳波先生将在线就公司业绩、公司治理、发展战略、经营状况和可持续发展等投 资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与。 特此公告 本公司及董事会全体成员保证信息披露内容的真实 ...

Core Viewpoint - The announcement indicates that Zhonghong Medical's subsidiary, Jiangxi Kelong Medical Device Manufacturing Co., Ltd., has received a change registration document for a new product, a visual respiratory oxygen mask, from the Jiangxi Provincial Drug Administration [2] Group 1 - The product name is "visual respiratory oxygen mask" [2] - The registration involves changes in model specifications, structural composition, and product technical requirements [2]

证券代码：300981 证券简称：中红医疗 公告编号：2025-081 中红普林医疗用品股份有限公司 关于子公司江西科伦医疗器械制造有限公司完成医疗器械 变更注册的公告 二、对公司的影响及风险提示 上述医疗器械注册证的变更是在原有注册证的基础上根据实际情况及相关 标准进行的相应变更。可视呼吸吸氧面罩领域相关产品的实际销售情况取决于未 来市场的推广效果，产品销售及利润贡献具有不确定性，目前尚无法预测上述产 品对公司未来业绩的影响，敬请相关投资者给予关注并注意投资风险。 三、备查文件 1.《医疗器械变更注册（备案）文件》； 2.《中华人民共和国医疗器械注册证》。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特此公告 中红普林医疗用品股份有限公司 中红普林医疗用品股份有限公司（以下简称"公司"）子公司江西科伦医疗 器械制造有限公司于近期取得江西省药品监督管理局颁发的《医疗器械变更注册 （备案）文件》。具体变更情况如下： 一、基本信息 | 产品名称 | 注册证编号 | 注册分类 | 变更内容 | 备注 | | --- | --- | --- | --- | --- ...

Core Viewpoint - The company, Zhonghong Medical, is primarily engaged in the export of medical devices and consumables, utilizing an ODM direct sales model, which allows it to design and produce products for overseas brand owners [2][4]. Group 1: Company Overview - Zhonghong Medical is a state-owned enterprise controlled by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [5]. - The company was established on December 22, 2010, and went public on April 27, 2021. Its main business includes the research, production, and sales of high-quality nitrile gloves, PVC gloves, and other disposable protective gloves [9]. - As of June 30, 2025, the company had 20,200 shareholders, with an average of 19,502 circulating shares per person, reflecting a 9.52% increase from the previous period [10]. Group 2: Financial Performance - For the first half of 2025, Zhonghong Medical achieved a revenue of 1.238 billion yuan, representing a year-on-year growth of 7.76%. However, the net profit attributable to the parent company was 5.7429 million yuan, a significant decrease of 82.35% compared to the previous year [10]. - The company's overseas revenue accounted for 81.56% of total revenue, benefiting from the depreciation of the RMB [4]. Group 3: Product and Market Development - Zhonghong Medical showcased its products at the 12th Beijing Pet Expo, highlighting its veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, providing multiple infusion modes and safety [2]. - The company emphasizes innovation and digital technology integration in product development, aiming to become a leading provider of intelligent and innovative medical solutions [3]. Group 4: Market Activity - On September 3, Zhonghong Medical's stock fell by 1.77%, with a trading volume of 85.5734 million yuan and a turnover rate of 1.55%, resulting in a total market capitalization of 5.953 billion yuan [1]. - The stock has seen a net outflow of 7.3092 million yuan from main funds today, indicating a trend of reduced holdings by major investors [6][7].